AI tools for regulatory affairs at a small biotech

Regulatory work at a twenty person company is two jobs wearing one title. One of them is documents and it is governed. The other is coordination, it is governed by nothing, and it is where the deadlines actually get missed.

The disclosure comes first because it decides whether the rest is relevant. The system described here is not a submission tool. It does not assemble or publish a dossier, it is not a validated document management system, it produces nothing that satisfies electronic records and signatures requirements, and nothing it writes is a controlled document. Anything that will be inspected, versioned under change control, or filed with an agency needs a system built and qualified for that purpose. This is not one, and configuring it harder does not make it one.

What is left is the half nobody sells software for at this company size: the running state of the regulatory work. Who owes which section, by when. What the agency actually asked in the meeting, in their words, and what your side committed to in reply. Which of last month's questions are still open. What the notice window on the vendor contract is, and when it closes.

The regulatory job that is not documents

Take a pre-submission meeting. The written record afterwards is one document. The operational residue is thirty items: an assay characterization your CMC lead said would be ready, a justification the agency was not persuaded by and wants supported, a commitment your team made verbally about how a study would be reported, a nonclinical gap you agreed to address in a later amendment. Six weeks later, the reliable version of that list exists in one person's head and in a thread they can mostly find.

A system that reads your mail and your meeting transcripts holds each of those as a dated open item with a person attached, files the correspondence to the program it belongs to, closes what an incoming message resolves, opens what it creates, and drafts your reply for approval. It never sends anything on its own. It brings the promise back on the morning it starts to matter rather than at the meeting where you discover it never happened.

Why the coordination half is where things break

Because it has no system and no owner. A company with an outsourced regulatory consultant, a CMC lead who is also running manufacturing, and a founder who signs everything has three people holding fragments of one deadline. The document work is disciplined precisely because it is governed. The coordination work is undisciplined precisely because nobody audits it, and it is what slips first when a program gets tight.

That pattern repeats across every function at this company size, which is the argument on the operations half of drug development. The version next door, with the same line drawn in the same place, is AI in clinical operations at a small biotech, and the boundary written out for the commercial side is AI agents for pharma.

Two constraints before you evaluate anything

It is single seat. One install, one person, one mail identity. Your CMC lead's commitment is captured as a thing for you to check on, not as a task assigned to them, and the system will not message anyone on your team or at your consultancy.

And the files are yours, in plain text on your own machine, which is a portability property rather than a data residency one. The model does not run on your laptop, so anything the system reads goes over the API to the model provider. Scope what it may see at install, narrow it whenever you like, and keep anything under a partner obligation or a confidentiality agreement outside it.

If the trial side is the pressure rather than the filing side, the clinical trial management software comparison is the more useful page, and knowledge management in pharma covers the category argument. Everything else in this set is indexed at AI for life sciences.